News | December 11, 2025
Bristol Myers Squibb unveils breakthrough Lymphoma data
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Subscribe To Our Newsletter & Stay Updated
